Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;12(6):593-601.
doi: 10.1007/s10194-011-0388-3. Epub 2011 Sep 22.

Chronic migraine plus medication overuse headache: two entities or not?

Affiliations
Review

Chronic migraine plus medication overuse headache: two entities or not?

Andrea Negro et al. J Headache Pain. 2011 Dec.

Abstract

Chronic migraine (CM) represents migraine natural evolution from its episodic form. It is realized through a chronicization phase that may require months or years and varies from patient to patient. The transition to more frequent attacks pattern is influenced by lifestyle, life events, comorbid conditions and personal genetic terrain, and it often leads to acute drugs overuse. Medication overuse headache (MOH) may complicate every type of headache and all the drugs employed for headache treatment can cause MOH. The first step in the management of CM complicated by medication overuse must be the withdrawal of the overused drugs and a detoxification treatment. The goal is not only to detoxify the patient and stop the chronic headache but also to improve responsiveness to acute or prophylactic drugs. Different methods have been suggested: gradual or abrupt withdrawal; home treatment, hospitalization, or a day-hospital setting; re-prophylaxes performed immediately or at the end of the wash-out period. Up to now, only topiramate and local injection of onabotulinumtoxinA have shown efficacy as therapeutic agents for re-prophylaxis after detoxification in patients with CM with and without medication overuse. Although the two treatments showed similar efficacy, onabotulinumtoxinA is associated with a better adverse events profile. Recently, the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical program proved that patients with CM, even those with MOH, are the ones most likely to benefit from onabotulinumtoxinA treatment. Furthermore, it provided an injection paradigm that can be used as a guide for a correct administration of onabotulinumtoxinA.

PubMed Disclaimer

References

    1. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746 - PubMed
    1. Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Steiner TJ, International Headache Society The international classification of headache disorders, 2nd edn (ICHD-II)—revision of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2005;25:460–465. doi: 10.1111/j.1468-2982.2005.00878.x. - DOI - PubMed
    1. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication overuse headache. Lancet Neurol. 2010;9:391–401. doi: 10.1016/S1474-4422(10)70008-9. - DOI - PubMed
    1. Mehlsteibl D, Schankin C, Hering P, Sostak P, Straube A. Anxiety disorders in headache patients in a specialised clinic: prevalence and symptoms in comparison to patients in a general neurological clinic. J Headache Pain. 2011;12:323–329. doi: 10.1007/s10194-011-0293-9. - DOI - PMC - PubMed
    1. Stovner LJ, Andree C. Prevalence of headache in Europe: a review of the Eurolight project. J Headache Pain. 2010;11:289–299. doi: 10.1007/s10194-010-0217-0. - DOI - PMC - PubMed

MeSH terms